research Presumptive Albendazole Toxicosis in 12 Alpacas
High doses of albendazole can be deadly for alpacas.
Search
for
Sort by
Research
570-600 / 1000+ results
research Audiological abnormalities in patients with alopecia areata
People with alopecia areata may be more likely to have a certain type of hearing loss.
research Commentary on a Randomized Placebo-Controlled, Double-Blind, Half-Head Study to Assess the Efficacy of Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia
PRP treatment increased hair density, especially in men and younger patients with AGA.
research Systematic review and indirect treatment comparisons of ritlecitinib against baricitinib in alopecia areata
Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
research Comparative Evaluation of Oral Baricitinib and Tofacitinib in Alopecia Areata: A Retrospective Cohort Study Based on SALT Scores
Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
research HrQoL in hair loss‐affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety
Personality traits and anxiety affect hair loss patients' quality of life.
research Clinical Assessment of Alopecia Areata Severity and Validating the Patient Experience: A Vodcast
Clinicians should use evidence-based tools and consider mental health when assessing alopecia areata to guide treatment.
research QSAR Analysis of a Series of Hydantoin‐based Androgen Receptor Modulators and Corresponding Binding Affinities
Researchers developed reliable models to predict how well certain compounds bind to androgen receptors, emphasizing the importance of atomic electronegativity.
research 52709 Patient-Reported Outcomes for Scalp, Eyebrow and Eyelash Hair Loss in Patients with Severe Alopecia Areata Treated with Baricitinib: 152 Week Results from two Phase 3 Clinical Trials
Baricitinib helps long-term hair regrowth in severe alopecia areata patients.
research Congenital triangular alopecia: A close mimicker of alopecia areata
CTA is often mistaken for AA but doesn't respond to steroids and may require hair transplantation.
research The Anti-Flyaway/Frizz Effect by Inducing the α-Helical Structure Transition of Hair
ATG effectively reduces hair frizz without damaging hair strength.
research A phase I study of MK-5108, an oral aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors.
MK-5108 is safe and shows potential against tumors, especially alone.
research ANALYSIS OF ADVERSE DRUG REACTIONS (ADRs) AND THEIR SEVERITY IN BREAST CANCER PATIENTS TREATED WITH THE DOCETAXEL-DOXORUBICIN REGIMEN AT SULTAN AGUNG ISLAMIC HOSPITAL
Most adverse reactions to the treatment were mild, with nausea being the most common.
research Long-lasting Antimicrobial Effect Achieved via Immobilization of Antimicrobial Agents on Hair Shaft
Treated hair can fight dandruff and odor even after several washes.
research Study on hair root lipids of female androgenetic alopecia based on UPLC‐Q‐TOF / MS results
research Development of squamous cell carcinoma from erythroplasia of Queyrat following photodynamic therapy
Photodynamic therapy may not work for erythroplasia of Queyrat and could lead to invasive squamous cell carcinoma.
research Timing of Initial Hair Regrowth and Clinical Trial-Defined Response Following Ritlecitinib Treatment in Patients With Alopecia Areata
Most patients with alopecia areata see significant hair regrowth within 93 days of starting ritlecitinib treatment.
research Les Rencontres d’Experts du Psoriasis : des recommandations pour la pratique quotidienne
Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
research BH15 Efficacy and safety of baricitinib in the management of severe alopecia areata over a 6-month period: a real-world experience
Baricitinib was effective and safe for severe hair loss treatment over 6 months.
research EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency
The guidelines ensure accurate genetic testing and reporting for 21-hydroxylase deficiency.
research Alopecia Areata Incognita: Current Evidence
Alopecia areata incognita causes sudden hair loss but usually improves with topical steroids.
research Notices
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research RAPID ALKALINIZATION FACTOR 22 is a key modulator of the root hair growth responses to fungal ethylene emissions in Arabidopsis
RALF22 is essential for root hair growth in response to fungal emissions in Arabidopsis.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Ritlecitinib Efficacy in Adolescents With Alopecia Areata: A Real‐World Experience
Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.
research Comparison of quality of life using hair-specific Skindex-29 between androgenetic alopecia and alopecia areata
Alopecia areata affects quality of life more than androgenetic alopecia.
research Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
Continued ritlecitinib treatment helps sustain hair regrowth in alopecia areata patients.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
GT20029 showed some hair growth improvement, but longer studies are needed for better results.